Effect of @entity619 on experimental XXXX .

@entity1 @entity932 @entity2657 @entity794 @entity619 @entity733 @entity35 @entity867
@entity619 has been used to manage @entity2657 in @entity1 with @entity932 . However, its administration has often been delayed or avoided for fear of adverse effects upon normal host responses to infection. An experimental model of @entity867 in the @entity35 was developed to determine if @entity619 produced adverse effects on immune competence and collagen deposition in the region of the @entity733 . @entity35 were inoculated with @entity794 and treated intraperitoneally each day with either @entity619 (0.25 mg/kg) or saline solution. Surviving animals were sacrificed at 4, 8, 12, or 18 days after treatment. The brains were examined grossly for @entity733 formation and microscopically for intensity of the inflammatory response, @entity733 diameter, and wall thickness. There were no differences in mortality rates, @entity733 production rates, or @entity733 diameters when groups were compared. The intensity of inflammatory response was similar in both groups. In the group sacrificed 8 days after inoculation, a delay in collagen deposition was apparent, manifested as a thinner @entity733 wall in the experimental group (mean: 17.8 mu in @entity619 -treated animals and 85 mu in saline-treated control animals: p = 1.0041). At 12 and 18 days after inoculation, there was no difference in @entity733 wall thickness between the control and experimental groups. Therapeutic doses of @entity619 had little effect on mortality rates, incidence of @entity733 production, or intensity of inflammatory response in the experimental animals. Thus, @entity619 did cause a delay in collagen deposition in the walls of experimental brain abscesses, but wall thickness 18 days after inoculation was not affected.
